Search Results - "Park, Sean S."

Refine Results
  1. 1

    Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer by Muldermans, Jonathan L., BS, Romak, Lindsay B., MD, Kwon, Eugene D., MD, Park, Sean S., MD, PhD, Olivier, Kenneth R., MD

    “…Purpose To review outcomes of patients with oligometastatic prostate cancer (PCa) treated with stereotactic body radiation therapy (SBRT) and to identify…”
    Get full text
    Journal Article
  2. 2

    PD-1 Restrains Radiotherapy-Induced Abscopal Effect by Park, Sean S, Dong, Haidong, Liu, Xin, Harrington, Susan M, Krco, Christopher J, Grams, Michael P, Mansfield, Aaron S, Furutani, Keith M, Olivier, Kenneth R, Kwon, Eugene D

    Published in Cancer immunology research (01-06-2015)
    “…We investigated the influence of PD-1 expression on the systemic antitumor response (abscopal effect) induced by stereotactic ablative radiotherapy (SABR) in…”
    Get more information
    Journal Article
  3. 3

    Synthesis and evaluation of anti-PD-L1-B11 antibody fragments for PET imaging of PD-L1 in breast cancer and melanoma tumor models by Bansal, Aditya, Lavoie, Roxane R., Lucien, Fabrice, Kethamreddy, Manasa, Wootla, Bharath, Dong, Haidong, Park, Sean S., Pandey, Mukesh K.

    Published in Scientific reports (22-08-2024)
    “…There is a critical need to non-invasively assess the PD-L1 expression in tumors as a predictive biomarker for determining the efficacy of anti-PD-1/PD-L1…”
    Get full text
    Journal Article
  4. 4

    Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy by Barham, Whitney, Guo, Ruifeng, Park, Sean S, Herrmann, Joerg, Dong, Haidong, Yan, Yiyi

    Published in Frontiers in immunology (02-02-2021)
    “…We report here a patient with stage IV mucosal melanoma treated with dual immune checkpoint inhibitor (ICI) therapy (Nivolumab/Ipilimumab) who experienced…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy by Davidson, Tara M, Foster, Nathan, Lucien, Fabrice, Markovic, Svetomir, Dong, Haidong, Winters, Jeffrey L, Park, Sean S, Orme, Jacob J

    Published in BMJ open (12-05-2022)
    “…BackgroundPatients with metastatic melanoma rely on PD-(L)1 immunotherapy, but only one-third of patients experience treatment response and all initial…”
    Get full text
    Journal Article
  7. 7

    Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer by Ahmed, Kamran A, Barney, Brandon M, Davis, Brian J, Park, Sean S, Kwon, Eugene D, Olivier, Kenneth R

    Published in Frontiers in oncology (2013)
    “…To report outcomes and toxicity for patients with oligometastatic (≤5 lesions) prostate cancer (PCa) treated with stereotactic body radiation therapy (SBRT)…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Delineation of Supraclavicular Target Volumes in Breast Cancer Radiation Therapy by Brown, Lindsay C., MD, Diehn, Felix E., MD, Boughey, Judy C., MD, Childs, Stephanie K., MD, Park, Sean S., MD, PhD, Yan, Elizabeth S., MD, Petersen, Ivy A., MD, Mutter, Robert W., MD

    “…Purpose To map the location of gross supraclavicular metastases in patients with breast cancer, in order to determine areas at highest risk of harboring…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Reirradiation for Locoregional Recurrent Breast Cancer by Fattahi, Sayeh, Ahmed, Safia K., Park, Sean S., Petersen, Ivy A., Shumway, Dean A., Stish, Bradley J., Yan, Elizabeth S., Remmes, Nicholas B., Mutter, Robert W., Corbin, Kimberly S.

    Published in Advances in radiation oncology (01-01-2021)
    “…Reirradiation poses a distinct therapeutic challenge owing to risks associated with exceeding normal tissue tolerances and possibly more therapeutically…”
    Get full text
    Journal Article
  15. 15

    Gemcitabine-Induced Radiation Recall Myositis: Case Report and Review of the Literature by Ravishankar, Adarsh, Park, Sean S., Olivier, Kenneth R., Corbin, Kimberly S.

    Published in Case reports in oncology (27-03-2018)
    “…Gemcitabine-induced radiation recall (GIRR) is a phenomenon wherein the administration of gemcitabine induces an inflammatory reaction within an area of prior…”
    Get full text
    Journal Article
  16. 16

    Benign Adenomyoepithelioma: An Unrecognised Precursor of Ductal Carcinoma in Situ in Patient With Lynch Syndrome by Park, Sean SW, Chan, Marcus, Velaiutham, Shanta, Vargas, Ana Cristina

    “…Currently, there is no robust evidence demonstrating a clear association between Lynch syndrome and non-malignant breast pathology such as adenomyoepithelioma…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases by Owen, Dawn, Laack, Nadia N., Mayo, Charles S., Garces, Yolanda I., Park, Sean S., Bauer, Heather J., Nelson, Kathryn, Miller, Robert W., Brown, Paul D., Olivier, Kenneth R.

    Published in Practical Radiation Oncology (01-03-2014)
    “…Stereotactic body radiation therapy (SBRT) is being applied more widely for oligometastatic disease. This technique is now being used for non-spine bony…”
    Get full text
    Journal Article
  20. 20

    Feasibility of proton transmission-beam stereotactic ablative radiotherapy versus photon stereotactic ablative radiotherapy for lung tumors: a dosimetric and feasibility study by Mou, Benjamin, Beltran, Chris J, Park, Sean S, Olivier, Kenneth R, Furutani, Keith M

    Published in PloS one (02-06-2014)
    “…Stereotactic ablative radiotherapy is being increasingly adopted in the treatment of lung tumors. The use of proton beam therapy can further reduce dose to…”
    Get full text
    Journal Article